Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Sell
15
ARWR Quote, Financials, Valuation and Earnings
Last price:
$19.46
Seasonality move
:
23.49%
Day range:
$19.18 - $20.21
52-week range:
$17.05 - $39.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.83x
P/B ratio:
13.06x
Volume:
3.9M
Avg. volume:
1.9M
1-year change:
-30.06%
Market cap:
$2.4B
Revenue:
$3.6M
EPS (TTM):
-$5.01
Analysts' Opinion
-
Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $47.43, Arrowhead Pharmaceuticals has an estimated upside of 143.66% from its current price of $19.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing -18.16% downside risk from its current price of $19.47.
Fair Value
-
According to the consensus of 12 analysts, Arrowhead Pharmaceuticals has 143.66% upside to fair value with a price target of $47.43 per share.
ARWR vs. S&P 500
-
Over the past 5 trading days, Arrowhead Pharmaceuticals has underperformed the S&P 500 by -9.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Arrowhead Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arrowhead Pharmaceuticals revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Arrowhead Pharmaceuticals reported revenues of --.
Earnings Growth
-
Arrowhead Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arrowhead Pharmaceuticals reported earnings per share of -$1.37.
Enterprise value:
2.1B
EV / Invested capital:
--
Price / LTM sales:
12.83x
EV / EBIT:
--
EV / Revenue:
11.77x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-3.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $243.2M | $240.7M | -- | $16.1M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$178.5M | -$205M | -$601.1M | -$108.3M | -$162.2M | |
| EBITDA | -$162.7M | -$175.7M | -$561.5M | -$99.9M | -$153.1M | |
| Diluted EPS | -$1.68 | -$1.92 | -$5.01 | -$1.02 | -$1.37 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $322.4M | $384.6M | $405.3M | $416.5M | $695.5M | |
| Total Assets | $522.5M | $710.1M | $691.9M | $765.6M | $1.1B | |
| Current Liabilities | $40.7M | $146.5M | $138.9M | $105.5M | $103.2M | |
| Total Liabilities | $60.7M | $301.3M | $273.6M | $478.4M | $948.7M | |
| Total Equity | $461.8M | $408.8M | $418.3M | $287.2M | $191.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$136.1M | -$153.9M | -$462.9M | -$25.9M | -$137.2M | |
| Cash From Investing | -$5.4M | -$96.2M | -$420.1M | $30.5M | -$222.9M | |
| Cash From Financing | $65.2M | $253.1M | $870.5M | $821K | $389.1M | |
| Free Cash Flow | -$188.9M | -$330.6M | -$604.3M | -$89.8M | -$161.5M | |
ARWR
Sector
Market Cap
$2.4B
$44.6M
Price % of 52-Week High
48.87%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-30.06%
-29.09%
Beta (5-Year)
0.906
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$21.34
200-day SMA
Sell
Level
$23.71
Bollinger Bands (100)
Sell
Level
19.24 - 23.9
Chaikin Money Flow
Sell
Level
-138.7M
20-day SMA
Sell
Level
$22.49
Relative Strength Index (RSI14)
Sell
Level
39.36
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-96.3508
50-day SMA
Sell
Level
$21.10
MACD (12, 26)
Sell
Level
-0.18
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
202.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.5259)
Sell
CA Score
(Annual)
Level (-4.4045)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.179)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Stock Forecast FAQ
In the current month, ARWR has received 7 Buy ratings 5 Hold ratings, and 0 Sell ratings. The ARWR average analyst price target in the past 3 months is $47.43.
-
Where Will Arrowhead Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arrowhead Pharmaceuticals share price will rise to $47.43 per share over the next 12 months.
-
What Do Analysts Say About Arrowhead Pharmaceuticals?
Analysts are divided on their view about Arrowhead Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arrowhead Pharmaceuticals is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Arrowhead Pharmaceuticals's Price Target?
The price target for Arrowhead Pharmaceuticals over the next 1-year time period is forecast to be $47.43 according to 12 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is ARWR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arrowhead Pharmaceuticals is a Buy. 7 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARWR?
You can purchase shares of Arrowhead Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arrowhead Pharmaceuticals shares.
-
What Is The Arrowhead Pharmaceuticals Share Price Today?
Arrowhead Pharmaceuticals was last trading at $19.46 per share. This represents the most recent stock quote for Arrowhead Pharmaceuticals. Yesterday, Arrowhead Pharmaceuticals closed at $19.47 per share.
-
How To Buy Arrowhead Pharmaceuticals Stock Online?
In order to purchase Arrowhead Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
